• Login as Editor
    View Item 
    •   Yeshiva Academic Institutional Repository
    • Albert Einstein College of Medicine (AECOM)
    • Albert Einstein College of Medicine: Doctoral Dissertations
    • View Item
    •   Yeshiva Academic Institutional Repository
    • Albert Einstein College of Medicine (AECOM)
    • Albert Einstein College of Medicine: Doctoral Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Staphylococcal enterotoxin K: A potential new target for immunotherapy against Staphylococcus aureus

    Thumbnail

    Date
    2015
    Author
    Aguilar, Jorge L.
    Metadata
    Show full item record
    Share
    Abstract
    Staphylococcus aureus is a major human pathogen with an extraordinary arsenal of virulence factors. The staphylococcal enterotoxins (SEs) are a family of secreted toxins with superantigenic properties. Neutralization of these superantigens has been shown to be protective in animal models of sepsis and toxic shock. SEK is a newly described superantigen that is one of the most prevalent SEs in clinical isolates, and is the only one to be associated with the community-acquired MRSA strain, USA300. However, studies into the expression and biological significance of this toxin are lacking. Using murine monoclonal antibodies, we developed a capture ELISA for the specific and sensitive measurement of SEK in biological fluids. Using this ELISA, we observed detectable levels of SEK secretion by all clinical isolates that encode sek. Analysis of these measurements from 36 isolates representing various MRSA and MSSA strains revealed significantly higher secretion of SEK by MRSA strains that co-encode SEB. However, in the setting of infection, we demonstrate that there is comparable accumulation of SEK in abscesses regardless of whether the infecting strain exhibits low or high in-vitro secretion of SEK. We then test the capacity of these mAbs to inhibit the superantigenic effects of SEK, and to protect mice from SEK intoxication and S. aureus septicemia. In-vitro, we demonstrate that these mAbs inhibit SEK-induced proliferation of human PBMCs in a dose-dependent manner. Using BALB/c mice, we then show that intraperitoneal administration of SEK results in lethality within 24 hours, and that pretreatment with a combination of mAb-4G3 (IgG2b) and mAb-5G3 (IgG1) protects mice from SEK-induced lethality. In the setting of sepsis, treatment with this combination of mAbs also protects mice from challenge with a blood-borne isolate of CA-MRSA strain USA300. Furthermore, septic mice that received mAb treatment in conjunction with vancomycin exhibit less morbidity than mice that received vancomycin alone. Taken together, our work demonstrates that SEK is commonly present in the setting of infection, and may contribute more to S. aureus pathogenesis than previously appreciated. Moreover, the monoclonal antibodies described in these studies have the potential to be further developed into diagnostic and therapeutic modalities.
    Permanent Link(s)
    https://ezproxy.yu.edu/login?url=http://gateway.proquest.com/openurl?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&res_dat=xri:pqm&rft_dat=xri:pqdiss:3664080
    https://hdl.handle.net/20.500.12202/1546
    Citation
    Source: Dissertation Abstracts International, Volume: 77-01(E), Section: B.;Advisors: Joshua D. Nosanchuk; Bettina C. Fries.
    *This is constructed from limited available data and may be imprecise.
    Collections
    • Albert Einstein College of Medicine: Doctoral Dissertations [1674]

    Yeshiva University Libraries copyright © 2021  DuraSpace
    YAIR Self-Deposit | YAIR User's Guide | Take Down Policy | Contact Us
    Yeshiva University
     

     

    Browse

    AllCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    Login as Editor

    Statistics

    View Usage Statistics

    Yeshiva University Libraries copyright © 2021  DuraSpace
    YAIR Self-Deposit | YAIR User's Guide | Take Down Policy | Contact Us
    Yeshiva University